Cardiff Oncology (CRDF) announced the appointment of Mani Mohindru as president and CEO, following her time as interim CEO, and that she will continue as a member of the board. The company also appointed Josh Muntner as CFO and Ajay Aggarwal as COO, effective April 6 and April 27, respectively. Previously, Muntner served as CFO of Imvax. Most recently, Aggarwal served as senior VP and head of clinical development at Aclaris Therapeutics (ACRS).
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRDF:
- Cardiff Oncology Formalizes Executive Departures Amid Strategic Review
- Cardiff Oncology advances onvansertib program in colorectal cancer
- Cardiff Oncology price target lowered to $6 from $10 at Piper Sandler
- Cardiff Oncology: Promising Onvansertib Data and Solid Cash Runway Support Buy Rating and $10 Price Target
- CRDF Earnings Report this Week: Is It a Buy, Ahead of Earnings?